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Background: How cells decipher the duration of an external signal into different transcriptional outcomes is poorly
understood. The hormone gastrin can promote a variety of cellular responses including proliferation, differentiation,
migration and anti-apoptosis. While gastrin in normal concentrations has important physiological functions in the
gastrointestine, prolonged high levels of gastrin (hypergastrinemia) is related to pathophysiological processes.
Results: We have used genome-wide microarray time series analysis and molecular studies to identify genes that
are affected by the duration of gastrin treatment in adenocarcinoma cells. Among 403 genes differentially regulated
in transiently (gastrin removed after 1 h) versus sustained (gastrin present for 14 h) treated cells, 259 genes
upregulated by sustained gastrin treatment compared to untreated controls were expressed at lower levels in the
transient mode. The difference was subtle for early genes like Junb and c-Fos, but substantial for delayed and late
genes. Inhibition of protein synthesis by cycloheximide was used to distinguish between primary and secondary
gastrin regulated genes. The majority of gastrin upregulated genes lower expressed in transiently treated cells were
primary genes induced independently of de novo protein synthesis. This indicates that the duration effect of gastrin
treatment is mainly mediated via post-translational signalling events, while a smaller fraction of the differentially
expressed genes are regulated downstream of primary transcriptional events. Indeed, sustained gastrin treatment
specifically induced prolonged ERK1/2 activation and elevated levels of the AP-1 subunit protein JUNB. Enrichment
analyses of the differentially expressed genes suggested that endoplasmic reticulum (ER) stress and survival is
affected by the duration of gastrin treatment. Sustained treatment exerted an anti-apoptotic effect on serum
starvation-induced apoptosis via a PKC-dependent mechanism. In accordance with this, only sustained treatment
induced anti-apoptotic genes like Clu, Selm and Mcl1, while the pro-apoptotic gene Casp2 was more highly
expressed in transiently treated cells. Knockdown studies showed that JUNB is involved in sustained gastrin induced
expression of the UPR/ER stress related genes Atf4, Herpud1 and Chac1.
Conclusion: The duration of gastrin treatment affects both intracellular signalling mechanisms and gene
expression, and ERK1/2 and AP-1 seem to play a role in converting different durations of gastrin treatment into
distinct cellular responses.
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Although the cellular response to one particular ligand
is usually specific to a given cell type [1], some studies
have shown that the duration [2-5] or concentration
[4,6] of the external stimuli may also influence the tran-
scriptional program and cell fate decision. Gene expres-
sion profiling in a pancreatic beta cell model treated
with glucose and cAMP has shown that the majority of
genes regulated in sustained treated cells were not regu-
lated by transient (1 h) treatment, indicating that beta
cells can produce drastically different transcriptional
outputs in response to different durations of metabolic
stimuli [2]. Glauser et al. [3] later showed that sustained
elevated glucose promotes long-term phosphorylation of
extracellular signal-regulated kinases (ERK1/2) followed
by sustained changes in the activator protein 1 (AP-1 )
subunits composition as well as in AP-1 controlled gene
expression. Hence, the authors suggested that in transi-
ently (1 h) treated cells the ERK1/2 activation is too
short to stabilize downstream gene expression. In human
keratinocytes (HaCaT), sustained transforming growth
factor beta (TGFβ) treatment induces a more persistent
phosphorylation of the primary intracellular mediator
SMAD2 than short pulses, and this may be critical for
cell fate determination like cell growth arrest in this cell
system [4]. Others have observed that a group of tumour
necrosis factor (TNF) upregulated genes which remain
at high levels in the sustained mode for 10 h, quickly
returned to baseline if TNF was removed after 6 h [5].
However, in which way the duration of external signals
affects molecular and biological responses has only been
explored in a few cell systems and the mechanisms are
still not well characterized.
The peptide hormone gastrin is the central regulator
of gastric acid secretion and plays a prominent role in
regulation of growth and differentiation of gastric and
colonic mucosa [7,8]. Gastrin signals via the gastrin/
cholecystokinin-2 (CCK2) receptor [9], and promotes a
variety of cell or tissue specific outcomes including pro-
liferation, survival, anti-apoptosis, differentiation and mi-
gration [7,10]. In normal physiological conditions,
gastrin levels are transiently upregulated in response to
a meal. Prolonged elevated blood levels of gastrin
(hypergastrinemia) can occur as a consequence of e.g.
atrophic gastritis or pharmacologic inhibition of gastric
acid secretion, which interrupts negative feedback
mechanisms on gastrin producing G-cells residing in
the gastric mucosa [10]. Recently it was shown that
the gastrin promotor can be activated by disease asso-
ciated Helicobacter pylori strains via the EGFR/Raf/
MEK/ERK cascade [11]. Both hypergastrinemia and
mutational activation of the CCK2 receptor have been
linked to development of neuroendocrine gastrointes-
tinal tumours (carcinoids) [7]; and gastrin and CCK2Rare reported to be upregulated in human pancreatic
adenocarcinoma [12,13].
Since transiently increased gastrin levels have import-
ant physiological functions in the gastrointestine, while
sustained high gastrin levels (hypergastrinemia) are re-
lated to pathophysiological processes [7,8,10,14], it is of
interest to examine how the duration of gastrin treat-
ment affects gene expression and molecular responses.
We have therefore conducted the present study to
examine how adenocarcinoma cells respond to transient
versus sustained gastrin signalling and to identify charac-
teristic differences between downstream biological re-
sponses. To do this, we analysed genome-wide time
series data of gastrin-regulated gene expression which
compared treatment in the transient (1 h) versus sus-
tained (14 h) mode. We used data from additional gas-
trin response time series experiments to identify
dependence on de novo protein synthesis related to tran-
scriptional timing (early, delayed, late) for genes that are
upregulated in the sustained mode (compared to un-
treated controls) and lower expressed in transiently
treated cells. Enrichment analysis of genes differentially
regulated in transient versus sustained gastrin signalling
suggested that pathways related to ER stress, cell sur-
vival and anti-apoptosis were affected by duration of
gastrin signalling. Indeed, several genes known to be in-
volved in these pathways were expressed at lower levels
in cells treated in the transient mode as compared to
cells treated in the sustained mode. Furthermore, the
anti-apoptotic effect of gastrin on serum starvation-
induced apoptosis was dependent on sustained treat-
ment, and our results indicate that the anti-apoptotic
effect of gastrin involves PKC/ERK1/2 signalling. Sus-
tained gastrin treatment induced prolonged ERK1/2 ac-
tivation and elevated levels of the AP-1 subunit protein
JUNB. The important role of ERK1/2 and AP-1 in
converting different durations of gastrin treatment into
distinct transcriptional responses was strengthened by
our findings that knock down of JUNB reduced gastrin-
mediated transcriptional activation of genes related to
the ER stress and survival pathways. Overall, our work
may contribute to a better understanding on how a cell
deciphers the durations of gastrin induced signalling
into specific cellular responses.
Results and discussion
Identification of genes that are differentially regulated by
transient versus sustained gastrin signalling
To investigate the mRNA transcriptome in response to
varying duration of gastrin treatment, we performed
genome-wide microarray time series experiments in the
adenocarcinoma cell line AR42J. We treated the cells in
a sustained mode (14 h of continuous presence of gas-
trin) and in a transient mode (gastrin was removed after
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analysis of the time series gene expression responses
identified 259 genes with lower and 144 genes with
higher expression in cells treated with gastrin in transi-
ent versus sustained mode (Additional file 1: Table S1).
The 403 differentially expressed genes were visualized in
a cluster analysis heat map (Figure 1B). The upper partTransient (1h) versus sustained (14h)
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Figure 1 Gene expression in transiently and sustained gastrin
treated cells. A: Schematic representation of stimulation protocol.
Post confluent AR42J cells were serum starved for 20–24 h before
10 nM gastrin was added. Sustained treated cells (continuous
presence of gastrin) were harvested at 9 different time points
between 1 and 14 h. Transiently treated cells (gastrin removed after
1 h) were harvested at 8 different time points between 1.5 and 14 h.
Untreated control cells were harvested at time point zero and
throughout the time course (10 time points). B: Heat map of genes
differentially expressed in transiently versus sustained treated cells.
Temporal gene expression profiles of genes up- and down-regulated
in sustained treated cells compared to untreated controls were
hierarchical clustered and matched to temporal gene expression in
transiently treated cells compared to untreated controls. The heat
map shows average temporal gene expression in two independent
experiments. The dendrogram is related to the hierarchical
clustering of the first independent experiment with sustained
treated cells.of the heat map shows that the 144 genes expressed at
higher levels in the transient mode are downregulated
by sustained gastrin treatment compared to untreated
controls, while the 259 genes with lower expression in
the transient mode (lower part of heat map) are
upregulated by sustained gastrin treatment. The heat
map further illustrates that differences in gene expres-
sion between cells treated in the transient and sustained
mode were subtle at 1.5 h and 2 h, while substantial dif-
ferences were apparent at time points after 2 h. The
most striking overall trend for these 403 genes is that
their transient mode expression levels after 4 h are simi-
lar to their levels in untreated cells, while they are
clearly elevated or reduced in the sustained mode. These
observations comply with our results from an earlier
microarray 24 h time series study which showed that the
regulation of several hundred genes was affected by gas-
trin signalling duration and that globally, gene expres-
sion levels returned earlier to baseline in cells subjected
to transient (2 h) treatment compared to sustained treat-
ment (Additional file 2: Accession number: E-MTAB-
123). Thus, our results indicate that sustained gastrin
signalling induces a transcriptional programme that dif-
fers significantly from the transcriptional response to
transient gastrin signalling.
To search for molecular responses affected by the dur-
ation of gastrin treatment, the 403 genes exhibiting dif-
ferential regulation in transiently versus sustained
treated cells (Additional file 1) were subjected to path-
way enrichment analysis using the MetaCore tool of
GeneGo package [15]. We found that high scoring ca-
nonical pathway and networks were related to
apoptosis-survival-development as well as to stress re-
sponses with a focus on the unfolded protein response
(UPR), endoplasmic reticulum (ER)-stress, DNA damage
and cell cycle (Table 1). Gene Ontology (GO) biological
process enrichment analysis of the 259 genes with lower
expression in transiently versus sustained treated cells
also identified cellular responses to unfolded proteins as
significantly enriched (Additional file 3: Table S2).
Enriched GO processes associated with the 144 genes
with higher expression in the transient mode were re-
lated to cell cycle phases and mitosis (Additional file 3:
Table S3). Thus, it seems that sustained gastrin treat-
ment is required for activation of genes involved in ER
stress/survival (Additional file 3: Table S2), while many
genes that are less downregulated by transient treatment
encode proteins that promote cell proliferation (Additional
file 3: Table S3).
ER stress/UPR is increasingly recognized to play a role
in tumourigenesis as well as in cell homeostasis [16-18].
Thus, our novel findings that gastrin i) regulate ER
stress/UPR genes and ii) does so in a signal duration-
specific manner are highly interesting. Depending upon
Table 1 Enrichment analysis
P-values Differentially expressed genes
Enrichment by GeneGo pathway maps
Apoptosis and survival_Endoplasmic reticulum stress
response pathway
6,910E-05 ATF-4, GRP78, C/EBP zeta, IP3R1, HERP, DNAJC3, ERP5
Reproduction_GnRH signalling 7,392E-05 PER1, JunB, ATF-3, EGR1, IP3 receptor, Dynamin-1, HDAC5, c-Fos
DNA damage_ATM / ATR regulation of G2 / M checkpoint 1,262E-04 Wee1, Cyclin B, GADD45 alpha, Cyclin A, CDK1 (p34)
Development_Growth hormone signalling via PI3K/AKT
and MAPK cascades
1,485E-04 JunB, C/EBP zeta, 4E-BP1, EGR1, C/EBPbeta, c-Fos
Development_Hedgehog and PTH signalling pathways in
bone and cartilage development
6,180E-04 EGR1, Smoothened, Ihh, Cyclin A, c-Fos
Enrichment by GeneGo process networks
DNA damage_Checkpoint 1,639E-05 CIA/ASF1, PCNA, Wee1, Cyclin B, GADD45 alpha, Cyclin B2, ATF-3,
Cyclin A1, 14-3-3 theta, Cyclin A, CDK1 (p34), CDK6, 14-3-3
Cell cycle_Mitosis 5,376E-05 Tubulin beta, Kid, PARD6A, Wee1, Cyclin B, CSE1L, Cyclin B2, TTK,
CAS-L, MKLP1, Dynamin-1, Cyclin A, CDK1 (p34), PARD6, Dynamin
Protein folding_Response to unfolded proteins 3,657E-04 ATF-4, ERp44, GRP78, HSP70, Calreticulin, HERP, DNAJC3, SELS
Canonical pathways and networks most significantly associated with the 403 genes differentially expressed (p<0.05) in transient versus sustained gastrin treatment
shown in the heat map in Figure 1B and in Additional file 1. The 5 pathways and 3 networks with lowest p-values are shown as determined by the MetaCore tool
of GeneGo package [15]. Enrichment analysis by GO process is found in Additional file 3: Tables S2 and S3.
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provide either survival signals by activating adaptive and
anti-apoptotic pathways, or death signals by inducing
cell death programs [19]. As illustrated by the selected
genes shown in Figure 2, sustained gastrin treatment
was required for increased expression of the main regu-
lator of the UPR, Hspa5 (BiP/Grp78), the transcription
factor Atf4 and the downstream mediators Herpud1,
Ddit3 (Chop) and Chac1 [18-21]. Since HERPUD1 is
reported to mediate cell protection via the stabilization
of ER Ca2+ homeostasis [22], its activation indicates a
possible mechanism for enhanced cell survival by
sustained gastrin treatment. In contrast, the ATF4 target
gene Ddit3 (Chop), and DDIT3 target gene Chac1 en-
code proteins associated with the pro-apoptotic effect of
the UPR [21,23]. Our results demonstrate that sustained
gastrin treatment is required for induction of several ER
stress/UPR genes and that the proteins encoded by these
genes are associated with both pro-survival and pro-
apoptotic effects. Thus, it cannot be directly deduced
from these results in which direction the subsequent cel-
lular response will be affected.
The anti-apoptotic effect of gastrin is well documented
[24-27], and it is therefore of interest to take a closer
look at the relation to apoptosis among the genes differ-
entially regulated in the transient versus sustained mode.
The pro-apoptotic Casp2 exhibits higher expression
levels in the transient mode than in the sustained mode,
while the anti-apoptotic genes Mcl1, Itpr1, Selm and Clu
were more strongly increased by sustained gastrin treat-
ment (Figure 3). We have previously shown that CLU is
required for the anti-apoptotic effect of gastrin in our
AR42J adenocarcinoma cell line model [24]. As a versatilestress-induced chaperone, CLU is suggested to be involved
in protein homeostasis via unfolded protein and ER stress
responses [28], and was recently shown to function co-
operatively with GRP78 (Bip) to mediate anti-apoptotic ef-
fect in the mitochondria pathway [29]. MCL1, a member
of the Bcl-2 protein family which inhibits release of cyto-
chrome c from mitochondria [30], has previously been
shown to be involved in the anti-apoptotic effect of gastrin
in human adenocarcinoma cells (AGS-GR) stably trans-
fected with the gastrin/CCK-2 receptor [31]. The ITPR1
receptor mediates Ca2+ release from ER and may be in-
volved in mediating anti-apoptosis by interacting with
anti-apoptotic members of the Bcl-2 family, including
MCL1 [32], while SELM is shown to decrease Ca2+ release
from ER in response to oxidative stress and reduce apop-
totic cell death [33]. Taken together, our gene expression
microarray analysis indicates that sustained but not transi-
ent gastrin treatment affects the balance between apop-
tosis and survival via several cross linked mechanisms
including communication between ER and mitochondria
which is critical for cellular decision making [29].
Sustained gastrin treatment inhibits serum starvation-
induced apoptosis via a PKC-dependent mechanism
To examine the effect of gastrin signalling duration on
cell survival, we induced apoptosis in AR42J cells by
serum starvation for 72 h and measured caspase activity
in cells subjected to sustained or transient gastrin treat-
ment. We found that sustained gastrin treatment signifi-
cantly reduced effector caspase activity (Figure 4A),
which is in accordance with our previous results using
both TUNEL and caspase assay for detection of apop-
totic cells [24]. This anti-apoptotic effect was not
BA
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Figure 2 Genes involved in the unfolded protein response (UPR) differ in transiently versus sustained gastrin treated cells. A: Schematic
presentation of the three signalling pathways initiated by the stress sensors IRE1, PERK and ATF6 in the UPR. The green circles indicate genes
differentially expressed in transiently versus sustained gastrin treated cells. IRE1, PERK and ATF6 are associated with the protein chaperone BiP
(HSPA5/GRP78) in their inactive state. In response to stress, unfolded proteins accumulate and bind to BiP, leading to release and activation of
the three stress sensors and activation of their respective pathways: IRE1 activates and initiates nonconventional splicing of Xbp1 mRNA. PERK
phosphorylates eIF2α leading to a general attenuation of translational initiation and a selective induction of ATF4 translation. ATF6 transits to the
Golgi where it is cleaved to yield a cytoplasmic fragment which moves into the nucleus. XBP1, ATF4 and ATF6 activate a wide variety of UPR
target genes, including BiP, Chop, Herp and Chac1 [16,20,21]. B: Data from two independent time series microarray experiments showing time
profiles for UPR genes differentially expressed in transiently versus sustained gastrin treated cells. Left panels: The data were extracted from a time
series experiment where sustained gastrin treated cells were harvested at 10 different time points between 15 min and 14 h. The samples from
untreated control cells were harvested at time zero and throughout the time course (11 time points). The mRNA expression level for untreated
(open dots) and sustained gastrin treated (black dots) cells are shown as normalized log2-transformed signal intensities (N=2). Right panels:
Gastrin induced gene expression in transiently (grey lines) and sustained (black lines) treated cells (stimulation protocol presented in Figure 1).
The data is shown as mean fold induction relative to untreated cells at the same time point (N=2).
Selvik et al. BMC Genomics 2013, 14:429 Page 5 of 19
http://www.biomedcentral.com/1471-2164/14/429detected in cells treated with gastrin in a transient mode
(Figure 4B). Thus, manifestation of the gastrin-induced
anti-apoptotic effect which is well documented in litera-
ture [24-27], requires sustained gastrin treatment and is
not induced when cells are exposed to gastrin for only
1 hour.
Since both the PI3K/AKT (PKB) pathway and ERK1/2
activation have been shown to be important in mediatingthe biological effects of gastrin, including anti-apoptosis
[25,26], we next set out to determine the involvement of
these two signalling pathways in our anti-apoptosis model
system. Involvement of ERK1/2-signalling was assayed by
the use of a PKC-inhibitor, since ERK1/2 activation has
been shown to be mediated by PKC-Src/Ras/Raf/MEK/
ERK1/2 cascade and/or by direct activation of Raf by PKC
in the gastrin response [9]. The anti-apoptotic effect of











































































































































































































Figure 3 (See legend on next page.)
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(See figure on previous page.)
Figure 3 Pro- and anti-apoptotic genes are differentially expressed in transiently and sustained gastrin treated cells. The panels show
gene expression time profiles for selected apoptosis-associated genes, differentially expressed in transiently versus sustained gastrin treated cells.
Data from two independent microarray experiments are shown as described in the legend to Figure 2B. Casp2: caspase 2; Mcl1: myeloid cell
leukemia sequence 1; Itpr1: inositol 1,4,5-trisphosphate receptor, type 1 (synonym: Ip3r1); Selm: selenoprotein M; Clu: clusterin.
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PI3K inhibitor (Figure 4C). In the presence of the PKC in-
hibitor gastrin still resulted in a small decrease in caspase
3/7 activity. However, this decrease was smaller than in
the absence of the PKC-inhibitor, and the anti-apoptotic
effect was no longer statistically significant (Figure 4D).
We therefore conclude that PKC and its downstream ef-
fector ERK1/2 may play a decisive role in the sustained
gastrin-induced anti-apoptotic effect. This observation
complies with results reported by others showing that a
specific inhibitor of the ERK1/2 activator MEK1 blocked
gastrin-induced anti-apoptosis in AR42J cells [26].
Genes that require sustained gastrin treatment for late
upregulation include both primary and secondary
responders
Cellular decision making in response to growth factors
like gastrin is driven by transcriptional cascades involv-
ing primary response genes dominated by regulators of
transcription and signal transduction and secondary re-
sponse genes which depend on de novo protein synthesis
and which include a high fraction of biological response
effector genes [34,35]. To investigate primary and sec-
ondary transcriptional response mechanisms underlying
the distinct biological responses to transient versus
sustained gastrin signalling, we focused on genes that
were markedly upregulated by gastrin and expressed at
lower levels in the transient mode. This 181 gene subset
can be grouped according to their time profiles as fol-
lows: 15 early genes peaking before 2 h (Figure 5 a-b);
50 delayed genes with peak expression at 2–4 h (Figure 5,
c-d); and 116 late genes upregulated 4–14 h (Figure 5, e-f)
(see Additional file 4: Table S4 for details). Genes de-
pendent on de novo protein synthesis were identified by
investigating the effect of the protein synthesis inhibitor
CHX on gastrin-induced gene expression responses. This
was done using data from a genome wide time series
experiment where the cells were treated by gastrin in
the absence and presence of CHX. To minimize misin-
terpretation due to the confounding effect of CHX
[34,36,37], the temporal profiles (7 time points; 0–10 h)
of treated and control cells were manually evaluated:
For those genes where the gastrin response in the pres-
ence of CHX was higher than the response with CHX
alone, the gene was classified as a primary gene not
dependent on de novo protein synthesis for gastrin-
induced expression. Gastrin induced genes that werenot upregulated in the presence of CHX were classified
as secondary genes, i.e., genes whose transcriptional ac-
tivation depends on de novo protein synthesis of one or
several factors that must be induced by gastrin previous
to these secondary genes. In cases where the effect of
gastrin could not be separated from the confounding ef-
fect of CHX, the gene was classified as uncertain.
Among the subset of 181 genes upregulated in sus-
tained treated cells and lower expressed in transiently
treated cells, 115 were classified as primary genes, 48 as
secondary and 18 as uncertain. The fraction of primary
genes was successively reduced from 100% among the
early genes to 40% among the late genes, while 43 of
the 48 secondary genes were found among the late gas-
trin induced genes (Table 2 and Additional file 4: Table
S4). Temporal expression data for genes in the subset
are shown in Additional file 5.
Even though we found that the fractions of primary
genes are reduced throughout the time course, most
(~70%) of the genes in the subset were classified as pri-
mary genes that do not depend on de novo protein syn-
thesis of upstream regulators (Table 2 and Additional
file 4: Table S4). This finding is somewhat surprising,
since previous reports have indicated that signal-
responsive genes are induced in waves where the group
of genes that requires de novo protein synthesis for ex-
pression and that is normally expressed in later waves, is
far more numerous than the group of early primary re-
sponse genes [39]. One explanation for our apparently
conflicting observations implying that a large fraction of
delayed and late genes are indeed primary genes, is that
we recorded the genome-wide transcriptome at a high
number of time points up to 14 h and in this way are
able to display the gastrin-induced transcriptional cas-
cades at high temporal resolution. This approach re-
vealed that in addition to early genes transcriptionally
activated within 2 h, also a high proportion of the de-
layed and late gastrin induced genes were upregulated
independently of de novo protein synthesis. The observa-
tion that many delayed induced genes were primary
genes are in accordance by results from a global time
series gene expression analysis in human glioblastoma
cells where Tullai et al. [40] showed that of the 133
genes induced within 4 h of human platelet-derived
growth factor (PGDF) treatment, 49 were primary im-
mediate early genes and 58 were primary delayed genes.
Detailed analyses of the relation between temporal gene
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Figure 4 Sustained gastrin treatment has an anti-apoptotic effect involving PKC-dependent mechanisms. Apoptosis was induced in
AR42J cells by serum starvation for 72 h and measured using Caspase Glo 3/7 assay. A: Caspase activity in cells treated with gastrin. B: Caspase
activity in untreated (U), sustained (S) or transiently (T) gastrin treated cells. C-D: Caspase activity in cells pretreated with inhibitors of PI3K (LY) or
PKC (GF) before cultivating in the absence (U) or presence of gastrin in a sustained mode (S). The data were normalized to the median intensity
of untreated cells in each independent experiment, and is shown as mean relative caspase 3/7 activity of three independent experiments
(6 technical replicates in each independent experiment). Error bars represent 95% CI. * Bonferroni-adjusted p-value < 0.05; significant difference
from untreated cells with or without inhibitor.
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http://www.biomedcentral.com/1471-2164/14/429expression profiles beyond 4 h and dependence on de
novo protein synthesis have to our knowledge not been
reported. Thus, our present study contributes to shed
light on these aspects of growth factor response tran-
scriptional dynamics.
To further characterize the subset of primary and sec-
ondary gastrin induced genes that were lower expressed
in the transient mode, we annotated their molecular
function based on Gene Ontology (GO) and literature
and grouped them into five main categories: regulation
of gene expression, signal transduction, transporters,
protein binding and enzymes. Regulators of gene expres-
sion are mainly found among the early and delayed
genes, while genes encoding signal transduction proteins
are spread throughout all temporal profile groups. Lategenes are dominated by effectors involved in transport,
enzyme and chaperone activity (see Table 2 and Additional
file 4 for details).
The group of late genes upregulated only by sustained
gastrin treatment comprises 65 primary and 43 second-
ary mRNA transcripts. Both primary and secondary late
gene products are involved in transport and protein
binding including chaperone activity. In addition, 35 late
genes are classified as enzymes (Table 2 and Additional
file 4: Table S4). Among these, enzymes are possible ef-
fector genes specifically associated with processes in the
exocrine pancreas: The protease coding genes Ctrc,
Prss1, Prss3, Sec11c and Cela3b are all highly expressed
in the pancreatic acinar derived AR42J cell-line. Sustained
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Figure 5 Temporal expression profiles of early, delayed and late gastrin-induced genes. A subset of 181 markedly gastrin-induced genes
with differing expression patterns in transient versus sustained mode were used to further characterize the temporal profiles. The data were
extracted from the independent time series microarray experiment where sustained gastrin treated cells were harvested at 10 different time
points between 15 min and 14 h. The samples from untreated control cells were harvested at time zero and throughout the time course (11 time
points). These genes were grouped by time profiles and peak expression (based on mean fold induction of sustained versus untreated cells at the
same time point, N=2) into 6 groups as illustrated in the heat map and panel a-f. See details in the main text.
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http://www.biomedcentral.com/1471-2164/14/429the mRNA levels of these enzymes (Additional file 5). The
genes were not induced in the presence of CHX and were
therefore classified as secondary gastrin-induced genes.
To our knowledge, gastrin has not previously been shown
to activate gene expression of these proteases.
Proteases can contribute to cancer development by
several mechanisms [41]. For example, in human pan-
creatic cancer, PRSS3 upregulates the ligand VEGFA via
the proteinase-activated receptor 1 (PAR1)-mediated
ERK1/2 pathway; and blockade of PRSS3-triggered ERK
signalling is shown to delay the progression of metastasis
and prolong the survival of mice bearing PRSS3-positive
human pancreatic tumours [42]. Others have shown that
gastrin enhances VEGFA gene expression in human
colon cancer cells stably transfected with a wild-type
CCK2 receptor [43]. Moreover, somatic mutations that
increase gastrin/CCK2 receptor activity increase the se-
cretion of VEGF and promote cell migration and angio-
genesis in colorectal and gastric cancer cells [44]. Ourfindings that upregulation of both Prss3 and Vegfa re-
quire sustained gastrin signalling indicate that the pro-
teins encoded by these genes may be involved in
hypergastrinemia associated pathophysiological pro-
cesses (see Figure 6 and discussion below).
Overall, scrutiny of the 181 selected temporal gene ex-
pression profiles revealed that the differences in transi-
ently versus sustained treated cells were subtle for early
response genes and more substantial for delayed or late
gastrin induced genes; and genes that are only
upregulated in the sustained mode comprise both pri-
mary and secondary genes (see Additional files 4 and 5
for extensive analysis). Exemplified time profiles for pri-
mary and secondary genes are shown in Figure 6. Pri-
mary early genes like c-Fos and Junb were upregulated
in both sustained and transiently gastrin treated cells.
However, their mRNA levels returned to baseline earlier
in cells treated in a transient versus a sustained mode
(Figure 6A). Delayed gastrin-responsive genes like
Table 2 Classification of primary and secondary gastrin induced genes lower expressed in transiently treated cells
Primary genes1 (N=115) Secondary genes2 (N=48)
Fraction
Per cent (%) genes in each group: 100 90 70 74 65 40 0 10 9 7 30 50
Temporal profiles3 a b c d e f a b c d e f
Molecular function 4 ( N=163) 5 9 16 20 48 17 0 1 2 2 22 21
Regulation of gene expression (N=22) 3 1 6 7 0 1 0 0 0 2 1 1
Transcription factors 3 0 3 5 0 0 0 0 0 0 0 1
Co-transcription factors 0 1 3 2 0 1 0 0 0 2 1 0
Signal transduction (N=44) 0 4 4 7 15 4 0 0 1 0 5 4
Receptors 0 0 0 2 1 1 0 0 0 0 1 0
Ligands 0 0 2 1 6 2 0 0 1 0 1 2
Intracellular signalling proteins 0 4 2 4 8 1 0 0 0 0 3 2
Transporters (N=15) 0 2 0 1 7 0 0 0 1 0 1 3
Channel and/or ER related 0 1 0 1 6 0 0 0 1 0 0 3
Other transporters 0 1 0 0 1 0 0 0 0 0 1 0
Protein Binding (N=23) 0 1 1 2 9 3 0 0 0 0 2 4
Chaperone activity 0 1 0 0 1 1 0 1 0 0 1 4
Other protein binding 0 0 1 2 8 2 0 0 0 0 1 0
Enzymes (N=39) 0 0 2 1 11 6 0 0 0 0 11 8
Proteases 0 0 2 0 4 1 0 0 0 0 0 6
Aminoacyl tRNA synthases 0 0 0 0 0 0 0 0 0 0 6 0
Other enzymes 0 0 0 1 7 5 0 0 0 0 5 2
Other functions (N=20) 2 1 3 2 6 3 0 0 0 0 2 1
1 Genes independent on de novo protein synthesis for gastrin induced expression (115 of 181 selected genes); 2 Genes dependent on de novo protein synthesis
for gastrin induced expression (48 of 181 selected genes); number of uncertain genes: N= 18; 3 Temporal profiles are illustrated in Figure 5; 4Molecular functions
are defined based on data from MetaCore tool of GeneGo package [15] Gene Ontology Annotation (UniProt-GOA) Database GOA [38] and literature.
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arily upregulated in the transient mode compared to un-
stimulated control at early time points, but only
sustained gastrin treatment induced high and prolonged
expression (Figure 6B). Interestingly, both late primary
genes like Maged2 and late secondary genes like Prss1
and Prss3 were only detected in cells treated in a
sustained mode (Figure 6C). This suggests that gastrin
directs duration-dependent gene expression via two dif-
ferent routes: i) via signal transduction mechanisms that
directly trigger transcriptional activation of primary
genes throughout both early and late stages of the time
course and ii) via mechanisms that depend on increased
expression of transcriptional regulators responsible for
upregulation of the late secondary genes.
Sustained gastrin treatment is required for extended
ERK1/2 activation
Since our data indicated that a large fraction of gastrin
induced genes differentially expressed in transiently versus
sustained treated cells are regulated by post-translational
direct signalling mechanisms, it was of interest to examinethe effect of the duration of gastrin treatment on signalling
pathways known to be activated by the gastrin/CCK2 re-
ceptor [9]. We therefore analysed AKT and ERK1/2 phos-
phorylation in cells treated with gastrin in a transient or a
sustained mode; starting at 75 minutes, i.e. 15 min after
gastrin was removed in the transient protocol. Our results
show that whereas ERK1/2 activity remains elevated for
several hours in cells treated in a sustained mode, the
level of phosphorylated ERK1/2 returned to base-line
within 60 min after gastrin was removed in transiently
treated cells (Figure 7A). The level of phosphorylated
AKT was low in both untreated and gastrin treated cells
in this time period (Figure 7B), which is in accordance
with finding by others showing that gastrin induced
AKT phosphorylation peaks 5–30 min after treatment
in AR42J cells [25] (i.e., in a time interval before the 75
minutes start of our observations). Thus, while AKT
phosphorylation is not prolonged by sustained gastrin
treatment, ERK1/2 phosphorylation, which is known
to involve upstream PKC [9], is strongly elevated at
later time points in sustained but not transiently
treated cells.





























































































































































































































































































































































































Figure 6 (See legend on next page.)
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(See figure on previous page.)
Figure 6 Time profiles for selected early (A), delayed (B) and late (C) genes differentially expressed in transiently versus sustained
gastrin treated cells. The panels show data from three independent time series microarray experiments. Left panels: mRNA expression level
(normalized log2-transformed signal intensities) for untreated (open dots) and sustained gastrin treated (black dots) cells. Experimental protocol is
described in the legend to Figure 2B. Middle panels: Gastrin induced gene expression in transiently (grey lines) and sustained (black lines) treated
cells. The data is shown as mean fold induction relative to untreated cells at the same time point (N=2; see Figure 1A for details). Right panels:
The effect of sustained gastrin treatment was measured in the presence (grey lines) and absence (black lines) of cycloheximide (CHX). The data is
shown as mean fold induction relative to either untreated cells (gastrin versus untreated) or relative to CHX treated cells (gastrin and CHX versus
CHX) at the same time point (1-10 h). The early primary genes c-Fos and Junb as well as the delayed primary gene Hdac5 are super-induced in
the presence of CHX. Thus, these genes are probably repressed by other gastrin-induced repressors dependent on de novo protein synthesis [37].
The late gene Maged2 is a primary gene. The delayed gene Vegfa and the late genes Prss1 and Prss3 (LOC362347) are secondary. Hdac5 is a
co-transcription factor involved in histone modification and shown to control cell-cycle progression and survival of human cancer cells [45].
VEGFA acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis and cell
growth, promoting cell migration, and inhibiting apoptosis [46]. Maged2 has been classified as a co-transcription factor and are found elevated in
e.g., goblet cell adenocarcinoids compared to normal mucosa [47]. Prss1 and Prss3 are discussed in the main text.
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is involved in directing cellular outcomes. For example,
nerve growth factor (NGF) and heregulin (HRG) induce
prolonged phosphorylation (i.e., activation) of ERK1/2
and subsequent differentiation in PC-12 and MCF-7
cells, respectively. Epidermal growth factor (EGF), on
the other hand, induces transient phosphorylation of
ERK1/2 and proliferation in the same cells [6,48-52].
Similarly, our findings that sustained gastrin treatment is
required for the sustained activation of the PKC /ERK1/
2-pathway as well as for PKC-dependent activation of
anti-apoptosis (Figure 4), indicate that the duration ofER
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Figure 7 Prolonged activation of ERK1/2 and expression of JUNB are
transiently gastrin treated cells were grown and harvested as described in
analysed at the indicated time points; starting 15 min after gastrin was rem
ERK1/2, total ERK1/2, phospho-AKT and total AKT in untreated (U), sustaine
show one representative of three independent experiments. C: The duratio
were measured by qRT-PCR analysis in cells treated by gastrin in a sustaine
one representative experiment (mean fold induction +/− SD of three techn
lysate at T0 and 4, 6 and 8 h of untreated (U), sustained (S) and transiently
independent experiments.ERK1/2 activation translates duration of gastrin signalling
into pro-survival cell fate in the AR42J adenocarcinoma
cell model system.
The magnitude of ERK activity can be regulated by
scaffold proteins [49]. We have recently shown that the
gastrin induced MAPK scaffold protein MEK partner 1
(MP1) is important for gastrin induced phosphorylation
of ERK1 and ERK2 in the human gastric adenocarcin-
oma cell line AGS-GR [53]. Qualitative and quantitative
differences in ERK activity can also be regulated at the
receptor level [49]. For example, the EGF receptor has
been reported to undergo rapid internalization andT0 STS U T U S TU
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Material and Methods. A-B: Activation of ERK (A) and AKT (B) were
oved in the transient protocol. Western Blot images of phospho-
d (S) and transiently (T) gastrin treated cells. T0: time point zero. Results
n and magnitude of mRNA expression of the AP-1 component Junb
d or transient mode relative to untreated controls at time point zero in
ical replicates). D: Western Blot image of JUNB protein in whole cell
(T) treated cells. Result show one representative of three
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sient ERK activation [49]. Less is known about how
prolonged gastrin stimulation affect the CCK2 (gastrin) re-
ceptor. However in our genome-wide time series experi-
ments we find that gastrin induces gene expression of
CCK2R and that the induction of Cck2r mRNA is some-
what higher in sustained versus transiently treated cells.
The Cck2r was highly expressed in the presence of CHX
which indicates that Cck2r is a primary gastrin-induced
gene and negatively feedback-regulated at the mRNA level
(data not shown). This is in accordance with findings by
others showing that gastrin increases CCK2R expression
at the mRNA and protein levels, both in cell cultures
[54,55] and in vivo [55]. More investigation is needed to
address the status of the gastrin receptor upon different
duration of gastrin treatment. However, our finding that
sustained gastrin treatment induces prolonged ERK1/2 ac-
tivation suggests that the gastrin receptor desensitizes
relatively slowly compared to the EGF receptor.
Molecular responses dependent on sustained gastrin
treatment involve AP-1
Sustained MEK/ERK activation is known to enhance the
activity of several members of the JUN- and FOS-family
of proteins [3,48] which are involved in transcription
regulation through homo- or heterodimeric AP-1 com-
plexes that can also involve proteins from the closely re-
lated CREB/ATF- and Maf-families [56]. Thus, it was of
interest to examine the potential involvement of AP-1 in
gastrin-mediated transcriptional activation of the primary



















































Figure 8 JUNB is involved in sustained gastrin induced expression of
(JUNB KD) and control cells (Firefly KD) were harvested at indicated time p
selected genes were measured by qRT-PCR analysis. Results show fold indu
(mean +/− SD of three technical replicates). The mRNA expression level of
Herpud1 mRNA levels were ~30% lower in JUNB KD cells at 1, 2 and 4 h, w
when JUNB was knocked down. Figures represent one of two independenWe found that binding sites for AP1, ATF and CREB
were overrepresented (Bonferroni corrected p value≤0.05)
among primary upregulated genes (Additional file 6: Table
S5). None of these transcription factor binding sites were
overrepresented among the secondary genes. Interestingly,
binding sites for AP-1 were overrepresented also among
primary genes with late expression profiles (d-f, Figure 5).
These findings indicate that AP-1 transcription factors
may play a central role in gastrin induced gene expression
that requires sustained treatment and is mediated via post
translational signalling events independent of de novo pro-
tein synthesis.
Detailed analysis of JUNB mRNA and protein showed
that although the difference at mRNA level was subtle
(Figure 7C), protein levels were substantially higher and
more prolonged in cells treated in the sustained mode
(Figure 7D). A potential mechanism underlying this obser-
vation may be stabilization of JUNB by phosphorylation
due to prevention of its degradation via proteasome path-
ways. Such inhibition of proteasome degradation by
sustained ERK1/2 activation has been reported in other
model systems [3,48]. Our results suggest that enhanced
JUNB protein levels downstream of ERK1/2 signalling
may play a decisive role in differential gene expression re-
sponses to sustained versus transient gastrin treatment.
To further examine the role of JUNB, we studied
gastrin-induced gene expression in cells where JUNB had
been knocked down by retrovirus-based shRNA (JUNB
KD). The efficiency of the RNAi was demonstrated by the
fact that Junb mRNA was suppressed 70% in JUNB KD



































ER stress/UPR related genes. Cells with JUNB knocked down
oints after sustained gastrin treatment, and mRNA expression level for
ction of gastrin treated cells relative to untreated control cells
Atf4 was 57% lower in JUNB KD cells compared to control cells at 4 h.
hile Chac1 was repressed 58% and 45% at 2 and 4 h, respectively
t experiments.
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expressed in transiently versus sustained gastrin treated
cells (Figure 2A), we found that JUNB knock down
suppressed gastrin induced transcriptional activation of
the transcription factor Atf4, involved in the PERK-eIF2α
pathway of the UPR, and the downstream mediator genes
Herpud1 and Chac1. Gastrin-induced Clu mRNA levels
were similar in JUNB KD and control cells indicating that
JUNB is not critically involved in the regulation of this
gene (Figure 8).
These results suggest that JUNB is involved in
sustained gastrin induced expression of Atf4 which may
subsequently affect downstream ATF4 mediated gene
expression, thus contributing to the differences seen be-
tween sustained and transient gastrin treatment. JUNB
can regulate gene transcription both positively and nega-
tively as partners in AP-1 dimers [57,58]. The stress
induced ATF4 transcription factor has numerous di-
merization partners including members of AP-1 and C/
EBP family of proteins [59]. In addition to Herpud1 and
Chac1, ATF4 is known to mediate upregulation of sev-
eral of the sustained gastrin regulated genes identified in
this work, e.g. Atf3, Mcl1 and Vegfa [59,60]. Recently,
JUNB was found to inhibit stress-induced apoptosis [61],
and ATF3 has been identified as a downstream target of
JUNB in the survival mechanism [62]. Taken together,
our results indicate that the distinct mRNA expression
patterns in cells treated in transient and sustained modes
are, at least in part, linked to the duration of ERK1/2 ac-
tivation and expression of the AP-1 components like
JUNB as well as the ATF subfamily proteins ATF4 and
ATF3 for which the mRNA expression levels are
prolonged only in the sustained mode.Conclusions
Genome-wide time series analyses are an important ap-
proach to capture the dynamics of stimuli-induced gene
expression responses over time [63]. The major contri-
bution of this study is that we by extensive time series
gene expression analysis and molecular studies
characterize the distinct effects of duration of gastrin
treatment on intracellular signalling events and gene ex-
pression in adenocarcinoma cells. We further show that
the differences in global gene expression were reflected
in distinct cellular responses in transiently and sustained
gastrin treated cells since our results point to the possi-
bility that a sustained high level of gastrin may affect the
survival/apoptosis balance. Our findings may contribute
to a better understanding of how gastrin-mediated regu-
lation of gene expression relates to pathophysiological
processes in response to high and sustained levels of
gastrin. Although we have limited our investigation to
one cell line in the present study, our findings provideinteresting new hypotheses for further studies in vivo as
well as other model systems.
Methods
Cells and reagents
The AR42J cells (rat pancreatic acinar cell derived,
ATCC, Rockville, MD) were cultured at 37°C in humidi-
fied 5% CO2 Dulbecco’s modified Eagle’s medium
(DMEM) containing 4.5 g/l glucose supplemented with
1% (v/v) penicillin-streptomycin, 0.1 mg/ml L-glutamine,
1 μg/ml fungizone, 1mM sodium pyruvate (all Gibco,
Invitrogen), and 15% fetal bovine serum (FBS, Lonza
BioWhittaker, Basel, Switzerland). Gastrin-17 (G-17) was
purchased from Sigma-Aldrich (St. Louis, MO). LY
294002 and GF 109203× were obtained from Calbiochem
(La Jolla, CA).
Time-series experiments in AR42J cells
The rat pancreatic acinar cell derived cell line AR42J has
been used as a model system to study exocrine pancreas
[64]. Furthermore, AR42J cells express gastrin receptors
endogenously and can therefore be used as a model sys-
tem to study gastrin responses like proliferation [65], dif-
ferentiation [66] and apoptosis [24-27]. In the time-
series experiment we treated cells with 10 nM gastrin in
accordance with several other studies investigating
gastrin-induced responses in the AR42J cell line
[25,54,67]. The cells were grown in 6-well plates (3 ×105
cells/well) for 72 h. Then the growth medium was
replenished with 2 ml serum-free DMEM, and the cells
serum starved for 20–24 h before adding gastrin.
Treated and untreated cells were grown in parallel and
harvested (pool of 2–3 technical replicates) at several
time points, as indicated in the figures. In experiments
with the protein synthesis inhibitor cycloheximide
(CHX), pre-treatments with CHX (10 μg/ml) were initi-
ated 30 min before gastrin was added. In experiments
with transient versus sustained gastrin treatment, the
growth medium of untreated and gastrin treated cells
was removed 1 h after gastrin treatment; the cells were
then washed with serum-free medium before fresh
serum-free medium with gastrin (sustained gastrin
treated cells) or without gastrin (transiently gastrin
treated or untreated cells) was added. The cells were
harvested for RNA isolation or protein lysate as de-
scribed below.
RNA isolation
Total RNA from AR42J cells and frozen oxyntic samples
was isolated using RNeasy Mini kit (Qiagen, German-
town, MD) according to the manufacturer’s instructions.
RNA quantity and purity was assessed using a Nanodrop
spectrophotometer (Nanodrop Technologies, Rockland,
DE), and RNA integrity controlled by measuring RIN
Selvik et al. BMC Genomics 2013, 14:429 Page 15 of 19
http://www.biomedcentral.com/1471-2164/14/429values using a Bioanalyser capillary gel electrophoresis
assay (Agilent Technologies, Palo Alto, CA). The RNA
samples were kept at −80°C until further processing.
Genome-wide gene expression analysis on Illumina
ExpressionBeadChips
RNA amplifications and hybridization were performed at
the NTNU Genomics Core Facilely (GCF). Briefly, RNA
was amplified with Ambion's IlluminaW TotalPrep RNA
Amplification kit (cat no AMIL1791) using 400 ng of
total RNA as input material. The in vitro transcription
(IVT) amplification that incorporated biotin-labeled nu-
cleotides was performed overnight (14 hours) at 37°C.
After the amplifications the cRNA concentrations where
checked with NanoDrop ND-1000 and cRNA quality
was controlled by BioRad’s Experion electrophoresis sta-
tion. A total of 750 ng of each biotin-labeled cRNA
sample was hybridized to Illumina’s RaRef-12-v1 Expres-
sion BeadChips at 58°C overnight (17 h) according to
the manufacturer’s instructions [68]. The hybridized
biotinylated cRNA was detected with 1ug/ml Cyanine3-
streptavidine, (GE Healthcare Biosciences) and the
Beadchips were scanned with Illumina BeadArray Reader
(Factor=1, PMT=521, Filter=100%). Numerical results
were extracted with Bead Studio v3.0.19.0 without any
normalization or background subtraction.
Data of gastrin-regulated gene expression which com-
pared treatment in the transient (1 h) versus sustained
(14 h) mode is a time course reference design with a
non-treated reference measured at each sampled time
point. The data was normalised by loess adjustment
within time points and average quantile normalised be-
tween time points. The data was analysed using the
Limma (ver. 3.12.1) Bioconductor package [69]. Repli-
cated treated and untreated (reference) samples were
compared using two separate linear models. The first
model covers each time point from 0–4 h and the sec-
ond and main model encompasses the remaining sam-
ples (6–14 h). Both models were tested for overall
significance across time using a moderated F-test. Genes
with a FDR adjusted p-value < 0.05 were taken as signifi-
cant. The ratio between treated and untreated (refer-
ence) sample at each time point was averaged between
biological replicates, and 403 significant genes were
visualised in a heat map (Figure 1B) where genes (rows)
are ordered by hierarchical clustering using Euclidean
distance and Ward agglomeration. Mapping between
Illumina probe identifiers and gene symbol was fetched
from official Illumina annotation files (RatRef-12_V1_
0_R5_11222119).
Database submission of microarray data
In addition to the time series experiment comparing
treatment in transient (1 h) versus sustained (14 h)mode, we used data from two other time series experi-
ments to analyse temporal time profiles of early and late
gastrin responsive genes and assess gene expression in
the presence and absence of the protein synthesis inhibi-
tor cyclohexamide (CHX) to distinguish primary and
secondary genes. The microarray data were prepared
according to minimum information about a microarray
experiment (MIAME) recommendations [70] and depos-
ited in the Array Express [71]. Detailed information
about the microarray designs and raw data files from the
experiments are accessible by use of these accession num-
bers: GSE32869, and E-MTAB-1268 (Illumina platform).
Enrichment analysis of pathways, GO-annotations and
transcription factor binding site (TFBS)
Canonical pathways and networks most significantly
associated by the genes differentially expressed in tran-
sienly versus sustained gastrin stimulated cells were de-
termined by GeneGo MetaCoreTM [15] enrichment
analysis with the general p-value threshold p<0.05 for
the data inputs. Molecular functions were defined based
on data from MetaCore tool of GeneGo package i.e.,
Network objects (object types), Gene Ontology Annota-
tion (UniProt-GOA) Database GOA [38] and literature.
Transcription factor binding site (TFBS) enrichment was
assessed for human orthologues of the rat genes by
using DAVID, Database for Annotation, Visualization
and Integrated Discovery, version 6.7 [72,73].
Real time qRT-PCR
cDNA synthesis was performed using Transcriptor First
Strand cDNA Synthesis Kit from Roche Diagnostics
GmbH (Mannheim, Germany), as described earlier [24].
After the cDNA synthesis reaction, the samples were di-
luted 1:3 in sterile water. Quantitative RT-PCR (qRT-
PCR) was performed using StepOnePlus, Real-Time
PCR System from Applied biosystems and B-R SYBR
Green SuperMix for iQ (Quanta Bioscience, Gaithers-
burg, MD). Each reaction contained SYBR Green
SuperMix (2×) (12.5 μl), sense primer (2.5 μl of 3 μM),
antisense primer (2.5 μl of 3 μM), cDNA template (2.5 μl),
and sterile water (5.0 μl). Quantitative PCR thermal cycling
program: 40 thermal cycles of 15 s at 95°C, 30 s at 60°C,
and 40 s at 72°C. A dissociation curve was made to con-
firm primer specificity. Primers: (Rattus Norvegicus): Clu,
sense: 5′-GCTCCATAGCCCAGCTTTAC-3′, antisense:
5′-ACTTCTCACACTGGCCCTTC-3′ [24]; B2m: sense:
5′-CGAGACCGATGTATATGCTTGC-3′, antisense: 5′-
GTCCAGATGATTCAGAGCTCCA-3′ [24]; Atf4, sense:
5′-GTTGGTCAGTGCCTCAGACA-3′, antisense: 5′-
CATTCGAAACAGAGCATCGA-3′ [74]; Junb, sense: 5′-
AGCTAGCCTCCACGGAACT-3′, antisense: 5′-CTCC
TGCTCCTCGGTGAC-3′; Herpud1, sense: 5′-TTGCA
CCTCGTGTGCAATGTGAGG-3′, antisense: 5′-ACTAG
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TTCCACAGGGGCAGCGATAAGAT-3′, antisense: 5′-
AACCTGGTATGCCACACCCCAAGTG-3′. Primers for
Junb, Herpud1 and Chac1 were designed using Clone
Manager 9 (Scientific & Educational Software, Cary, NC)
or Primer-Blast [75]. All samples were run in triplicates,
and relative mRNA expression levels were quantified using
the ΔΔCt-method [76] with B2m as reference gene.Western blot analysis
Cells were washed twice in PBS, and harvested in 400 μl
cold RIPA buffer (Thermo Scientific, Rockford, IL)
containing 8 μl Halt™ Protease Inhibitor Single-Use
Cocktail (100×) (Thermo Scientific) and 4 μl Halt™ Phos-
phatase Inhibitor Single-Use Cocktail (100×) (Thermo
Scientific) per well. The lysate was homogenized using a
syringe and needle (21 G), and cell debris removed by
centrifugation (15 min, 14000 ×g, 4°C). The supernatant
was stored at −80°C until further processing. The pro-
tein concentrations were measured using the PierceW
BCA Protein Assay Kit (Thermo Scientific) according to
the manufacturer’s instructions. Gel electrophoresis and
blotting were performed using the NuPAGE system from
Invitrogen according to the manufacturer’s instructions;
as previously described [24]. The membranes were
blocked in TBST (50 mM Tris·HCl pH 7.5, 150 mM
NaCl, 0.1% Tween 20) with 5% bovine serum albumin
(BSA) (Sigma-Aldrich) for 1 h at room temperature, in-
cubated with the primary antibody diluted in TBST with
1% BSA overnight at 4°C, and incubated with the sec-
ondary HRP-conjugated antibody diluted in TBST with
1% BSA for 2 h at room temperature. For detection of α-
tubulin (loading control), blocking, washing, and antibody
incubation were performed with SNAP i.d. Protein Detec-
tion System (Millipore, Billerica, MA) according to the
manufacturer’s instructions, using TBST with 1% BSA for
blocking and antibody dilution. Binding of secondary anti-
bodies was visualized by use of the SuperSignal West
Femto Maximum Sensitive Substrate (Thermo Scientific)
and Kodak Image Station 2000R (Kodak, Pittsburgh, PA).
The following antibodies were used: monoclonal
(mouse) anti-human α-Tubulin (reacts with mouse, rat
and human) (1:300; sc-5286, Santa Cruz Biotechnology),
polyclonal horseradish peroxidase (HRP) conjugated
(goat) anti-mouse (1:3000; PO447, DAKO), polyclonal
(rabbit) phospho-p44/42 MAPK (Erk1/2) (Thr202/
Tyr204) (1:1000; #9101, Cell Signaling), polyclonal
(rabbit) p44/42 MAPK (Erk1/2) (1:1000; #9102, Cell Sig-
naling), monoclonal (rabbit) JunB (1:1000; #3753 Cell
Signaling), polyclonal (rabbit) phospho-AKT (Ser473)
(1:1000; #9271, Cell Signaling) and polyclonal (rabbit)
AKT (1:1000;#9272, Cell Signaling), HRP-conjugated
goat anti-rabbit (1:1000; #7074, Cell Signaling).Stable knockdown (KD) of JUNB by retrovirus-based RNAi
Eight 97-mer shRNA oligoes were designed to target
Junb using the algorithm from [77]. The oligoes were
cloned into MSCV P2Gm FF retroviral transfer vector
(Addgene) using XhoI and EcoRI restriction enzymes
(New England Biolabs). Correct clones were verified by
sequencing. Packaged virus was obtained by co-
transfection of 293FT cells (ATCC) with 1μg MSCV
P2Gm FF transfer vector (Addgene), 0.5 μg MLV gag-pol
(Addgene), and 0.5 μg CMV-VSVg (Addgene) expression
vectors using Fugene6 (Roche) according to manufac-
turer’s protocol and as previously described [78].
Medium was replaced 24 h and 48 h after transfection,
293FT cell conditioned medium was collected, filtered
through a 0.45μm filter, and applied to AR42J cells with
4 μg/ml polybrene (Sigma) [78]. Infected AR42J cells
were GFP positive and selected with 2 μg/ml puromycin
(Sigma). The cell lines with most efficient knock down






AR42J cells (1.5 × 104) were seeded in white-walled 96-
well plates (Perkin Elmer). The cells were incubated for
one day before the growth medium was replenished with
150 μl serum-free DMEM with or without different doses
of gastrin (1–10 nM). After 1 h, the medium was again
replenished and gastrin added to cells treated in the
sustained mode. Cells were further incubated for 72 h to
induce apoptosis. Chemical inhibitors were added 30 min
before the gastrin treatment. Caspase activity was mea-
sured using the Caspase-Glo 3/7 assay from Promega
(Madison, WI) according to the manufacturer’s descrip-
tions. Luminescence was measured using Wallac 1420
Victor3TM plate reader (Perkin Elmer). All the data were
log-transformed before statistical analysis. For presenta-
tion, the data were transformed back to the original scale
and plotted as means with 95% confidence interval (CI) as
error bars. Student's t-test was used to evaluate statistical
significance, and we performed a Bonferroni correction
for multiple testing at 0.05 level in each analysis.
Additional files
Additional file 1: Table S1. The file contains information about
403 genes with significantly different mRNA expression levels (adjusted
p<=0.05) in cells treated with gastrin in a transient versus sustained mode
(Accession number GSE32869).
Additional file 2: The file includes results from an initial cDNA
microarray time series experiment (Accession number: E-MTAB-123).
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Graphical representation of experimental design of the two-colour cDNA
microarray hybridizations. Figure S2: Number of differentially expressed
genes. Figure S3: Analysis of microarray time series by dimension reduction
methods.
Additional file 3: Table S2. Enrichment analysis of 259 genes
significantly lower expressed in transiently versus sustained gastrin treated
cells. Table S3: Enrichment analysis of 144 genes significantly higher
expressed in transiently versus sustained gastrin treated cells. All 403
genes are shown in the heat map in Figure 1B and Additional file 1.
Additional file 4: Table S4. The file lists a subset of 181 gastrin-
induced probes (177 unique IDs) with differing expression patterns in
transient versus sustained mode which were used to further characterize
the temporal profiles including information about gene expression in the
presence and absence of a protein synthesis inhibitor (CHX) as well as
molecular functions. The data are extracted from independent time series
experiments in Accession numbers GSE32869 and E-MTAB-1268.
Additional file 5: Temporal profiles of gastrin-induced genes with
differing expression patterns in transient versus sustained mode
described in Figure 5 and Additional file 4: Table S4. Time profiles as
log2 expression data from three independent time series experiments are
shown for each individual gene. Upper panels: transiently or sustained
treated cells; Middle panels: sustained treated or untreated control cells.
Lower panels: gene expression in the presence and absence of the
protein synthesis inhibitor CHX.
Additional file 6: Table S5. Identification of overrepresented
transcription factor binding sites (TFBS) among the subset of upregulated
genes lower expressed in transiently gastrin treated cells (described in
Figure 5 and Additional file 4: Table S4). TFBS enrichment was assessed
for human orthologues of the rat genes by using DAVID version 6.7
(Bonferroni corrected p-values).
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